Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting malignant cell proliferation.

GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution aligned to EU regulatory standards. The product is manufactured under EU Good Manufacturing Practice and shipped under controlled conditions to ensure product integrity.

Imatinib acts on the BCR‑ABL tyrosine kinase pathway and is used in specific hematologic and solid tumours. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth in patients with KIT or PDGFRA mutations. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

Imatinib may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: fluid retention, often peripheral. - Fatigue: generalized tiredness. - Muscle cramps: intermittent skeletal muscle discomfort. - Diarrhea: loose stools. - Rash: mild skin eruption.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Myelosuppression: neutropenia, anemia, or thrombocytopenia. - Cardiotoxicity: heart failure or reduced left ventricular function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Imatinib, clinicians should consider several precautionary measures to minimize risk. - Baseline liver function: assess hepatic enzymes before initiating therapy. - Hematologic monitoring: perform regular CBC to detect neutropenia or anemia. - Cardiac assessment: evaluate cardiac function in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib levels and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may decrease absorption. - Anticoagulants (e.g., warfarin): imatinib may enhance anticoagulant effect. - Vaccines (live attenuated): potential reduced efficacy due to immunosuppression.